Q2 EPS Estimates for Fortress Biotech Raised by Roth Capital

Fortress Biotech, Inc. (NASDAQ:FBIO) – Analysts at Roth Capital increased their Q2 2025 earnings estimates for Fortress Biotech in a report issued on Tuesday, May 20th. Roth Capital analyst J. Wittes now expects that the biopharmaceutical company will post earnings of ($0.31) per share for the quarter, up from their previous forecast of ($0.43). The consensus estimate for Fortress Biotech’s current full-year earnings is ($3.28) per share. Roth Capital also issued estimates for Fortress Biotech’s Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($1.20) EPS and FY2026 earnings at ($0.45) EPS.

Fortress Biotech (NASDAQ:FBIO) last issued its quarterly earnings data on Monday, March 31st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.53. The firm had revenue of $15.12 million during the quarter, compared to the consensus estimate of $16.30 million.

Separately, Roth Mkm reaffirmed a “buy” rating and set a $16.00 price objective (up from $15.00) on shares of Fortress Biotech in a report on Tuesday, March 11th.

Fortress Biotech Stock Up 1.8%

Fortress Biotech stock opened at $1.73 on Thursday. Fortress Biotech has a twelve month low of $1.33 and a twelve month high of $2.89. The firm has a 50 day moving average price of $1.63 and a 200-day moving average price of $1.76. The company has a market capitalization of $51.16 million, a P/E ratio of -0.57 and a beta of 1.85.

Hedge Funds Weigh In On Fortress Biotech

A number of hedge funds have recently modified their holdings of the company. HB Wealth Management LLC increased its position in shares of Fortress Biotech by 6.1% in the first quarter. HB Wealth Management LLC now owns 113,350 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 6,500 shares during the period. PFG Investments LLC boosted its stake in shares of Fortress Biotech by 28.4% during the 1st quarter. PFG Investments LLC now owns 45,259 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 10,000 shares in the last quarter. Wolverine Trading LLC bought a new stake in shares of Fortress Biotech during the 4th quarter valued at about $26,000. PVG Asset Management Corp boosted its stake in shares of Fortress Biotech by 3.3% during the 4th quarter. PVG Asset Management Corp now owns 386,295 shares of the biopharmaceutical company’s stock valued at $782,000 after purchasing an additional 12,505 shares in the last quarter. Finally, Integrated Wealth Concepts LLC boosted its stake in shares of Fortress Biotech by 28.9% during the 4th quarter. Integrated Wealth Concepts LLC now owns 59,400 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 13,300 shares in the last quarter. Hedge funds and other institutional investors own 96.51% of the company’s stock.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.